Company: PolyProx Therapeutics
Job title: Professor, University of Cambridge; Chief Scientific Officer
Laura has over 20 years’ experience leading academic research in the field of protein engineering. She has a BA in Chemistry (Oxford) and PhD in Biochemistry (Cambridge). From 2003 to 2011 her group was located at the MRC Cancer Cell Unit in Cambridge UK, and she is currently a Professor in the Department of Pharmacology at the University of Cambridge. In 2019, she secured seed finance for PolyProx Therapeutics to develop biotherapeutics harnessing the cell’s quality-control machinery to destroy disease-associated proteins that cannot be targeted by conventional drug modalities.
Harnessing the Cell’s Degradation Machineries Nature’s Way to Manipulate Protein Stability 3:00 pm
• The common underpinning basis of the cell’s proteostasis network is molecular recognition involving the specific interactions of proteins with one another. The Polyproxin™ platform exploits our understanding of these interactions to harness proteostasis networks and thereby manipulate protein stability and disease outcome • The platform comprises libraries of target-engagement modules and degradation-inducing modules in…Read more
day: Day One